These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 4719108)

  • 41. Sentinel surveillance shows small decline in MMR coverage.
    Commun Dis Rep CDR Wkly; 1998 Sep; 8(36):317, 320. PubMed ID: 9782644
    [No Abstract]   [Full Text] [Related]  

  • 42. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age.
    Gatchalian S; Cordero-Yap L; Lu-Fong M; Soriano R; Ludan A; Chitour K; Bock HL
    Southeast Asian J Trop Med Public Health; 1999 Sep; 30(3):511-7. PubMed ID: 10774661
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months.
    Gans H; Yasukawa L; Rinki M; DeHovitz R; Forghani B; Beeler J; Audet S; Maldonado Y; Arvin AM
    J Infect Dis; 2001 Oct; 184(7):817-26. PubMed ID: 11528592
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CHRONOVAC VOYAGEUR: A study of the immune response to yellow fever vaccine among infants previously immunized against measles.
    Goujon C; Gougeon ML; Tondeur L; Poirier B; Seffer V; Desprès P; Consigny PH; Vray M;
    Vaccine; 2017 Oct; 35(45):6166-6171. PubMed ID: 28958813
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Measles and mumps antibody concentrations in newborns and their mothers--follow up first year of life].
    Hohendahl J; Peters N; Hüttermann U; Rieger C
    Klin Padiatr; 2006; 218(4):213-20. PubMed ID: 16819702
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A second dose of MMR vaccine for children in the United Kingdom.
    Commun Dis Rep CDR Wkly; 1996 Jul; 6(30):259. PubMed ID: 8755703
    [No Abstract]   [Full Text] [Related]  

  • 47. [Inoculation properties of live combined vaccine against measles and mumps].
    Vasil'eva GA; Slatin EA
    Zh Mikrobiol Epidemiol Immunobiol; 1983 May; (5):70-5. PubMed ID: 6880482
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The measles-mumps-rubella vaccination program in Finland.
    Redd SC; Wharton M; Hadler SC; Orenstein WA
    N Engl J Med; 1995 Apr; 332(16):1102-3. PubMed ID: 7898540
    [No Abstract]   [Full Text] [Related]  

  • 49. The timing of tuberculin tests in relation to immunization with live viral vaccines.
    Brickman HF; Beaudry PH; Marks MI
    Pediatrics; 1975 Mar; 55(3):392-6. PubMed ID: 1143978
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Persistence of antibody after administration of monovalent and combined live attenuated measles, mumps, and rubella virus vaccines.
    Weibel RE; Buynak EB; McLean AA; Hilleman MR
    Pediatrics; 1978 Jan; 61(1):5-11. PubMed ID: 263873
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antibody response following measles-mumps-rubella vaccine under conditions of customary use.
    Brunell PA; Weigle K; Murphy MD; Shehab Z; Cobb E
    JAMA; 1983 Sep; 250(11):1409-12. PubMed ID: 6887461
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Incubation vaccination ("post-exposure vaccination") with MMR vaccine during a mumps epidemic? The Pediatric Vaccine Counseling Unit].
    Wiersbitzky S; Bruns R; Beyer B
    Kinderarztl Prax; 1992 Oct; 60(7):207-8. PubMed ID: 1359187
    [No Abstract]   [Full Text] [Related]  

  • 53. Effectiveness of mumps virus given alone or in combination with live vaccines against measles and rubella.
    Nasibov MN; Yakovleva NV; Smorodintsev AA
    Prog Immunobiol Stand; 1970; 4():676-82. PubMed ID: 5482205
    [No Abstract]   [Full Text] [Related]  

  • 54. [Clinico-immunologic evaluation of a trivalent vaccine against measles, rubella and mumps].
    Schettini F; Manzionna MM; De Mattia D; Amendola F; Di Bitonto G
    Minerva Pediatr; 1989 Mar; 41(3):117-22. PubMed ID: 2747598
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protection of mumps in children with various underlying diseases: application of a live attenuated mumps and trivalent measles-rubella-mumps (MRM) vaccines in these children.
    Kanesaki T; Baba K; Tsuda N; Yabuuchi H; Yamanishi K; Takahashi M
    Biken J; 1986 Dec; 29(3-4):63-71. PubMed ID: 3304276
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The epidemiological impact of vaccination strategies in the Lazio Region].
    Faustini A; Giorgi-Rossi P; Sangalli M; Spadea T; Perucci CA
    Ann Ig; 2002; 14(4 Suppl 4):39-49. PubMed ID: 12389423
    [No Abstract]   [Full Text] [Related]  

  • 57. Evaluation of mumps antibodies after measles-mumps-rubella (MMR) vaccines.
    Ozaki K; Kuno-Sakai H; Kimura M
    Tokai J Exp Clin Med; 1987 Dec; 12(5-6):305-11. PubMed ID: 3508655
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Saliva antibody testing and vaccination in a mumps outbreak.
    Ramsay ME; Brown DW; Eastcott HR; Begg NT
    CDR (Lond Engl Rev); 1991 Aug; 1(9):R96-8. PubMed ID: 1669793
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Delayed results of vaccination of children with recurrent respiratory infections against measles and mumps].
    Liashenko VA; Krasnoproshina LI; Aleksander SK; Skhodova SA
    Zh Mikrobiol Epidemiol Immunobiol; 2010; (2):60-3. PubMed ID: 20465003
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Reactogenic properties and immunogenicity of measles and mumps vaccines when used by different procedures].
    Astabatsian MA; Bolotovskiĭ VM; Gelikman BG; Mikheeva IV
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Jun; (6):9-15. PubMed ID: 3751401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.